ambroxol has been researched along with Respiratory Distress Syndrome in 12 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate efficacy of high-dose oral ambroxol in acute respiratory distress syndrome (ARDS) with respect to ventilator-free days (VFD)." | 9.20 | High-dose Oral Ambroxol for Early Treatment of Pulmonary Acute Respiratory Distress Syndrome: an Exploratory, Randomized, Controlled Pilot Trial. ( Baranwal, AK; Murthy, AS; Singhi, SC, 2015) |
| "This study seeks to evaluate the potential benefits of high doses of ambroxol treatment for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) by conducting a meta-analysis based on randomized controlled trials (RCTs)." | 8.90 | Meta-analysis of high doses of ambroxol treatment for acute lung injury/acute respiratory distress syndrome based on randomized controlled trials. ( Deng, Q; Han, L; Li, S; Wan, X; Wu, X; Zhang, J; Zhang, Y, 2014) |
| "This study seeks to evaluate the potential benefits of high doses of ambroxol treatment for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) by conducting a meta-analysis based on randomized controlled trials (RCTs)." | 4.90 | Meta-analysis of high doses of ambroxol treatment for acute lung injury/acute respiratory distress syndrome based on randomized controlled trials. ( Deng, Q; Han, L; Li, S; Wan, X; Wu, X; Zhang, J; Zhang, Y, 2014) |
| "Ambroxol inhibited proinflammatory cytokines, reduced lung inflammation and accelerated recovery from LPS-induced ALI." | 3.72 | Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. ( Bai, C; Song, Y; Su, X; Wang, L, 2004) |
| "Ambroxol, a drug capable of elevating the phospholipid content in healthy rabbit lungs, was tested on two models of experimental lung injury, lung changes in sepsis induced by a peritonitis and in bromcarbamide intoxication." | 3.67 | Ambroxol increases the choline but not fatty acid incorporation into lung phospholipids in experimental lung disorders. ( Müller, B; von Wichert, P; Wilke, A, 1987) |
| "Ambroxol plays a role in facilitating synthesis and secretion of pulmonary surfactant protein A and relieves the lung tissue injury induced by paraquat poisoning." | 1.33 | [Influence of ambroxol on paraquat-induced lung tissue injury and change of pulmonary surfactant-associated protein A in the experimental rats]. ( Feng, L; Liu, JH; Lv, CH; Ma, YT; Shi, HW; Su, JL; Sun, ZP; Tian, YP, 2006) |
| "Ambroxol can inhibit lipid peroxidation and increase antioxidant activity, which may be one of the mechanisms in protecting lung tissue from hydrochloric acid-induced injury." | 1.32 | [Oxidative and anti-oxidative effects of ambroxol on acute hydrochloric acid-induced lung injury in rats]. ( Guo, QL; Wang, E; Wang, RK; Zhao, SP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, X | 1 |
| Li, S | 1 |
| Zhang, J | 1 |
| Zhang, Y | 1 |
| Han, L | 1 |
| Deng, Q | 1 |
| Wan, X | 1 |
| Baranwal, AK | 1 |
| Murthy, AS | 1 |
| Singhi, SC | 1 |
| Wang, WS | 1 |
| Guan, JY | 1 |
| Lu, QL | 1 |
| Su, X | 1 |
| Wang, L | 1 |
| Song, Y | 1 |
| Bai, C | 1 |
| Zhou, HY | 1 |
| Chang, YT | 1 |
| Lü, ZP | 1 |
| Zhao, SP | 1 |
| Guo, QL | 1 |
| Wang, RK | 1 |
| Wang, E | 1 |
| Ma, YT | 1 |
| Tian, YP | 1 |
| Su, JL | 1 |
| Shi, HW | 1 |
| Lv, CH | 1 |
| Sun, ZP | 1 |
| Liu, JH | 1 |
| Feng, L | 1 |
| Akkoca Yildiz, O | 1 |
| Dauberschmidt, R | 1 |
| Kuckelt, W | 1 |
| Bender, V | 1 |
| Hieronymi, U | 1 |
| Mrochen, H | 1 |
| Winsel, K | 1 |
| Zinsmeyer, J | 1 |
| Meyer, M | 1 |
| Disse, BG | 1 |
| Wilke, A | 1 |
| Müller, B | 1 |
| von Wichert, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ambroxol and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Meta-analysis of high doses of ambroxol treatment for acute lung injury/acute respiratory distress syndrome based on randomized controlled trials.
Topics: Ambroxol; Biomarkers; Cytokines; Expectorants; Gene Expression Regulation; Humans; Lung Injury; Oxid | 2014 |
[Ambroxol].
Topics: Ambroxol; Anti-Inflammatory Agents; Antioxidants; Asthma; Bronchial Hyperreactivity; Cystic Fibrosis | 2006 |
The pharmacology of ambroxol--review and new results.
Topics: Airway Resistance; Ambroxol; Animals; Bromhexine; Bronchitis; Chronic Disease; Humans; Infant, Newbo | 1987 |
2 trials available for ambroxol and Respiratory Distress Syndrome
| Article | Year |
|---|---|
High-dose Oral Ambroxol for Early Treatment of Pulmonary Acute Respiratory Distress Syndrome: an Exploratory, Randomized, Controlled Pilot Trial.
Topics: Administration, Oral; Ambroxol; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Bl | 2015 |
[Protective effects of ambroxol on lung injury during cardiacpulmonary bypass in patients undergoing valve replacement].
Topics: Adult; Ambroxol; Cardiopulmonary Bypass; Expectorants; Female; Heart Valve Prosthesis Implantation; | 2004 |
7 other studies available for ambroxol and Respiratory Distress Syndrome
| Article | Year |
|---|---|
[Clinical research on high-dosage ambroxol hydrochloride associated with ulinastatin in improvement of lung tissue injury of patients with paraquat poisoning].
Topics: Adult; Ambroxol; Expectorants; Female; Glycoproteins; Humans; Lung; Lung Injury; Male; Paraquat; Res | 2010 |
Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide.
Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Dexamethasone; Disease Mo | 2004 |
[Oxidative and anti-oxidative effects of ambroxol on acute hydrochloric acid-induced lung injury in rats].
Topics: Ambroxol; Animals; Female; Hydrochloric Acid; Lipid Peroxidation; Male; Malondialdehyde; Protective | 2004 |
[Influence of ambroxol on paraquat-induced lung tissue injury and change of pulmonary surfactant-associated protein A in the experimental rats].
Topics: Ambroxol; Animals; Immunohistochemistry; Lung; Male; Paraquat; Pulmonary Surfactant-Associated Prote | 2006 |
Effects of bromhexine metabolite VIII (NA 872) in an animal model of the respiratory distress syndrome.
Topics: Ambroxol; Animals; Blood Circulation; Bromhexine; Carbon Dioxide; Disease Models, Animal; Lactates; | 1980 |
[Ambroxol. Prophylaxis and therapy of pulmonary complications. Symposium on the occasion of the 12th International Sylt Week on Anesthesiology. 9 September 1998].
Topics: Ambroxol; Anesthesia; Dose-Response Relationship, Drug; Expectorants; Humans; Lung Diseases; Medicin | 1998 |
Ambroxol increases the choline but not fatty acid incorporation into lung phospholipids in experimental lung disorders.
Topics: Ambroxol; Animals; Bromhexine; Choline; Fatty Acids; Female; Lung; Lung Diseases; Male; Peritonitis; | 1987 |